<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837183</url>
  </required_header>
  <id_info>
    <org_study_id>20-001448</org_study_id>
    <nct_id>NCT04837183</nct_id>
  </id_info>
  <brief_title>Catheter Ablation of Ventricular Arrhythmia Reduces Skin Sympathetic Activity</brief_title>
  <official_title>Catheter Ablation of Ventricular Arrhythmia Reduces Skin Sympathetic Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine whether there is an increase in sympathetic nerve&#xD;
      activity before the onset of ventricular arrhythmias or irregular heartbeat rhythm. In&#xD;
      addition, this study is looking at the relationship between sympathetic nerve activity and&#xD;
      how patients with ventricular arrhythmias respond to catheter ablation treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 4, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 4, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in amplitude of skin sympathetic nerve activity</measure>
    <time_frame>Baseline, 24 hours post catheter ablation and approximately 3-6 months post-operative</time_frame>
    <description>measured in µV</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in LF/HF ratio</measure>
    <time_frame>Baseline, 24 hours post catheter ablation and approximately 3-6 months post-operative</time_frame>
    <description>low frequency (LF)/high frequency (HF) ratio of the skin sympathetic nerve activity</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients will undergo catheter ablation to control VA recommended by current guideline.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have sustained VA (VA ≥ 30s or receiving appropriate ICD therapies) are&#xD;
             presented to the clinic or admitted to the hospital within 7 days of episodes.&#xD;
&#xD;
          -  The causes of VA are associated with structural heart diseases including ischemic or&#xD;
             nonischemic cardiomyopathy (idiopathic cardiomyopathy, hypertrophic cardiomyopathy,&#xD;
             cardiac sarcoidosis or amyloidosis, and arrhythmogentic right ventricular dysplasia).&#xD;
&#xD;
          -  Subjects are 18 years of age and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced comorbid conditions with life expectancy &lt; 1 year.&#xD;
&#xD;
          -  Unwilling or unable to return for required follow-up visits.&#xD;
&#xD;
          -  Female patients who is pregnant or of childbearing potential and not on a reliable&#xD;
             form of birth control.&#xD;
&#xD;
          -  Pacing artifacts prevents Skin Sympathetic Nerve Activity (SKNA) analyses.&#xD;
&#xD;
          -  Allergic to skin patch electrodes.&#xD;
&#xD;
          -  Vulnerable populations (fetuses, neonates, pregnant women, prisoners,&#xD;
             institutionalized individuals).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong-Mei Cha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian W Liddell, BS</last_name>
    <phone>507-255-8717</phone>
    <email>Liddell.Brian@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian W Liddell, BS</last_name>
      <phone>507-255-8717</phone>
      <email>Liddell.Brian@mayo.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yong-Mei Cha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

